Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Drug, Healthcare and Patient Safety · Published 2022-09-01 · DOI 10.2147/dhps.s338050

Authors being retrieved — see the publisher record. https://doi.org/10.2147/dhps.s338050

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2022

Related articles